Literature DB >> 8663078

Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription.

P P Sayeski1, J E Kudlow.   

Abstract

Transforming growth factor-alpha (TGFalpha) gene transcription can be increased when arterial smooth muscle cells are exposed to supraphysiological concentrations of glucose, and this effect of glucose can be mimicked by glucosamine. To determine whether the metabolism of glucose to glucosamine is required for this glucose effect, the rate-limiting step in glucose metabolism to glucosamine through the enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT) was blocked using pharmacological and antisense strategies. We found that blockage of GFAT activity or expression significantly blunted the glucose-induced increase of TGFalpha expression. Blockage of GFAT also resulted in a decreased RL2 signal on intracellular proteins as detected by Western blotting and indirect immunofluorescence. The RL2 monoclonal antibody recognizes an epitope on proteins that contain N-acetylglucosamine and thus is a measure of protein glycosylation. Conversely, treatment of the cells with glucose and glucosamine resulted in an increase in the RL2 epitope on intracellular proteins. These results indicate that the metabolism of glucose to glucosamine is necessary for the transcriptional stimulation of TGFalpha expression in vascular smooth muscle cells by glucose. Furthermore, the level of glycosylation of some intracellular proteins can be modulated in response to physiological changes in the extracellular glucose concentration and the net activity of GFAT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663078     DOI: 10.1074/jbc.271.25.15237

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Identification of a biochemical link between energy intake and energy expenditure.

Authors:  Silvana Obici; Jiali Wang; Rahena Chowdury; Zhaohui Feng; Uma Siddhanta; Kimyata Morgan; Luciano Rossetti
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 2.  Plasma leptin and exercise: recent findings.

Authors:  Matthew W Hulver; Joseph A Houmard
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 3.  Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system.

Authors:  Norbert Fülöp; Richard B Marchase; John C Chatham
Journal:  Cardiovasc Res       Date:  2006-07-29       Impact factor: 10.787

Review 4.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

Review 5.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

Review 6.  From wavy hair to naked proteins: the role of transforming growth factor alpha in health and disease.

Authors:  Bhuminder Singh; Robert J Coffey
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

Review 7.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

8.  Influence of glucosamine on glomerular mesangial cell turnover: implications for hyperglycemia and hexosamine pathway flux.

Authors:  Leighton R James; Catherine Le; James W Scholey
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-10       Impact factor: 4.310

9.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

Review 10.  Mechanisms of disease: the oxidative stress theory of diabetic neuropathy.

Authors:  Claudia Figueroa-Romero; Mahdieh Sadidi; Eva L Feldman
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.